Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
N4 Pharma LSE:N4P London Ordinary Share GB00BYW8QM32 ORD 0.4P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.05p +0.47% 10.70p 77,412 10:44:45
Bid Price Offer Price High Price Low Price Open Price
10.50p 10.90p 10.70p 10.65p 10.65p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -1.93 -1.26 9.7

N4 Pharma (N4P) Latest News

More N4 Pharma News
N4 Pharma Takeover Rumours

N4 Pharma (N4P) Share Charts

1 Year N4 Pharma Chart

1 Year N4 Pharma Chart

1 Month N4 Pharma Chart

1 Month N4 Pharma Chart

Intraday N4 Pharma Chart

Intraday N4 Pharma Chart

N4 Pharma (N4P) Discussions and Chat

N4 Pharma Forums and Chat

Date Time Title Posts
22/1/201916:50N4 Pharma1,550
07/12/201810:53N4 Pharma - Making good drugs better.3,890

Add a New Thread

N4 Pharma (N4P) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
10:44:3710.7822,5002,424.38O
09:52:3810.7450,0005,370.00O
08:20:3110.794,912530.00O
2019-01-23 14:00:2810.502,036213.78UT
2019-01-23 12:39:5610.5115,0001,576.50O
View all N4 Pharma trades in real-time

N4 Pharma (N4P) Top Chat Posts

DateSubject
24/1/2019
08:20
N4 Pharma Daily Update: N4 Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker N4P. The last closing price for N4 Pharma was 10.65p.
N4 Pharma has a 4 week average price of 8.90p and a 12 week average price of 5p.
The 1 year high share price is 35.50p while the 1 year low share price is currently 3.35p.
There are currently 90,962,537 shares in issue and the average daily traded volume is 273,121 shares. The market capitalisation of N4 Pharma is £9,687,510.19.
17/1/2019
11:59
cf456: The share price can certainly move very quickly when it gets going: "we would point out that the share price rally in the first two months of 2018 that saw the shares move from under 10p to as high as 35p was almost exclusively driven by announcements relating to positive progress being made with Nuvec. Moreover, subsequent progress with Nuvec has been hugely positive." Worth watching closely for the next leg up.
17/1/2019
09:37
cf456: First Equity - Top 10 Micro-Cap Picks for 2019 "We believe that the shares are currently materially undervalued, with the wider market having failed to appreciate the potential value of Nuvec." "We are of the opinion that the current share price offers an incredibly attractive entry into a biotechnology that has genuine potential to make a real impact on the rapidly growing vaccines and therapeutics space." hTTps://gallery.mailchimp.com/d266f47cec87da1170bcd0f35/files/5bf0e4f5-88e8-428a-841e-63d25ffd8bf2/Top_10_Micro_Cap_Picks_Part_I.01.pdf
12/11/2018
04:34
hughwilson: featherby81 As much as it pains me to walk away from a fight, I do understand where you are coming from. You may have noted from a few posts back where I said that as much of the positive news for N4 was now near term that I was inclined to let the company news do the talking. In my opinion the news for N4 is going to be highly positive in the near term and that will result in a share price that is many multiples of where we are now in due course, so for the time being I will play it your way and resist from posting and allow the debate to focus on all the near term news which I expect will be highly positive for the company and its share price. And to end, no I am not David Farier, nor for Lewis did I ever say I was , but I am aware of his business activities in turnaround situations like this from which he is normally very successful. Just something else the mob got wrong.
11/11/2018
15:28
hughwilson: What I would like to see is an apology from all those posters who have been trying to deramp this stock during its time of uncertainty. Deramping by spreading lies and fear for their own personal gain to the detriment of real investors (myself included), that is the apology that I would like to see but that has about as much chance of platting fog. Lewis, I am confident in your ability in such a way that if I ever said will be an easy tweak then you would have found it. The fact that you have not been able to proves that it does not exist which is what I said and makes you a filthy liar along with all the other things you claim I said and did not. Your inability to prove to the contrary shows you up for the hateful vendetta that you have been waging against my person. In my opinion along with other investors is that it is time to move on from these personal vendetta`s. Given the vile and defamatory remarks I have suffered on this board I have more to be aggrieved about than most and yet my main interest remains the future of N4 which I see as being very positive with a share price of many multiples of where we are now. The future is looking extremely bright for N4 and that is now being recognized in the press and the share price. hTTps://www.thisismoney.co.uk/money/investing/article-6372161/SMALL-CAP-MOVERS-MySQUAR-edge-collapse-uncovering-900k-unauthorised-payments.html
10/11/2018
15:35
hughwilson: So getting back to the point, does this sound like a deal is being discussed and that a deal is likely within the next three months? That question goes out to all except Lewis because he is just a Hugh hater. If you agree that there is a real chance of a deal then in your experience what is the effect on the share price when a minoe like N4 signs a deal with a major like AZ? "agreeing terms for co-development of an optimized version of Nuvec(R) under an appropriate collaboration agreement." In my experience, we have seen rises of 200-300% even before the market opens. Who knows what will happen here but as I said before, AZ are not the only company that N4 are in discussion with. If you accept that interest in Nuvec is building then you know where the share price is heading.
27/9/2018
09:45
ch1rp: At current mcap, and in light of recent deals in this subsector, it's really not unreasonable to suggest that a single (and entirely realistic) RNS could see the share price do multiples.Market needs educating on this.Aim Chaos on Twitter:)))Buy when no confidence and share price low, not on the day the news arrives:)))
10/8/2018
12:19
jimbobaroony: Hugh, back in Feb when you were very bullish over N4P you accused me of deramping and posting "negative dribble". See below; "hughwilson7 Feb '18 - 20:12 - 1835 of 3883 As I said before, the Sildenafil is a reformulation of a proven drug to make it better. There is no basis for thinking N4's Viagra will be anything but successful. hughwilson7 Feb '18 - 21:53 - 1851 of 3883 The company itself is very bullish on its prospects. The company is ahead of its own timescales. It is already doing deals with the biggest pharmas in the world while being recognised snd funded by the British government. There are no negatives that I can see here and yet you spout nothing else but unsuported negative dribble. Don't pretend to be anything else (but a deramper)." This was becase I dared post the following suggesting that either could hammer the share price. "jimbobaroony 7 Feb '18 - 20:59 - 1843 of 3883 Edit For some yin to all your yang. Another catalyst (to drive share price).... - Delays / problems with their products - No deal announcements Pretty sure this is unlikely but its a possibility." I don't know how you can have the audacity to call us stupid!!! I am not in any way gloating at what has transpired (i am underwater here), however, it was always a possibility. Either you were too blind to see it, or didn't care as you had another agenda. Its one or the other!
03/2/2018
08:53
nick2412: Hugh, I guess the wording translates as MedImmune / AZ have the right to discuss and seek exclusivity whilst N4P retain the right to name their price. I think it would require a very large initial milestone payment for an exclusive license, or, alternatively, necessitate buying Nuvac outright for a sum that equates in the N4P share price to pounds rather than pence for AZ (or any other company for that matter) to achieve exclusivity. The studiy highlighting the differences between Nuvac and current / other DNA /RNA drug delivery methods should be published this quarter and perhaps before the Japan visit. Existing findings suggest that Nuvac will be in demand so the potential is a)a lucrative exclusive deal with AZ b) multiple licensing deals with different partners c) a bidding war to buy Nuvac outright. Early days but it's looking interesting to say the least.
03/7/2017
17:23
bdog51: I'm with you on that Flash. When the direction of travel reverses, the N4P share price can really motor. Bargain price down at these low levels right now. Just takes a bit of news flow to change the tide.
18/5/2017
11:50
someuwin: CEO owns 17% of the equity here. This is almost entirely from his own purchases on the market when this was ONZ (see repeated Holdings RNSs last year). Furthermore his consideration shares resulting from the new N4P listing are deferred until the N4P share price has been over 15p for 10 consecutive days. ...I don't think it will be too long before that situation occurs.
N4 Pharma share price data is direct from the London Stock Exchange
Your Recent History
LSE
N4P
N4 Pharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190124 11:07:08